Moreover, KMT2B had divergent effects on immunotherapy response, with higher KMT2B expression associated with response in melanoma patients (p = 0.043) and lower KMT2B expression linked to response in stomach adenocarcinoma patients (p = 0.001). Here, KMT2B is linked to melanoma.